- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Avalon GloboCare Forms Strategic Partnership with Major Biomedical Enterprise Da An Gene
Avalon GloboCare (OTCQB: AVCO), a leading global developer of cell-based technologies, announced that the Company has formed a strategic partnership with Da An Gene Co., Ltd, a major biomedical company publicly listed on the Shenzhen Stock Exchange (002030.SZ), to further optimize Avalon’s exosome-based technology, clinical development, as well as product commercialization. As quoted in the press …
Avalon GloboCare (OTCQB: AVCO), a leading global developer of cell-based technologies, announced that the Company has formed a strategic partnership with Da An Gene Co., Ltd, a major biomedical company publicly listed on the Shenzhen Stock Exchange (002030.SZ), to further optimize Avalon’s exosome-based technology, clinical development, as well as product commercialization.
As quoted in the press release:
“This strategic partnership with Da An Gene will significantly accelerate our product development and commercialization in the fields of liquid biopsy and in vitro diagnostics,” said David Jin, M.D., Ph.D., President and CEO of Avalon GloboCare, as well as co-CEO of its subsidiary GenExosome Technologies Inc. “The specialty of Da An’s genomic sequencing and profiling platform, in combination with our proprietary exosome isolation system and clinical expertise in regenerative medicine, will further establish Avalon’s leading role in precision and regenerative medicine,” added Dr. Jin.
Click here to read the full press release.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.